We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Consensus Estimate for the to-be-reported quarter’s revenues is pegged at $42.2 million, while the same for the bottom line is pinned at earnings of 34 cents per share.
Let us see how things are likely to have shaped up for ETON in the to-be-reported quarter.
Factors Likely to Influence ETON's Q3 Results
Eton currently has 12 commercial products and five additional candidates in late-stage development. Growth in several of these products, particularly Increlex, Alkindi Sprinkle, Galzin and Carglumic Acid, helped drive the company’s first-half performance.
Investors will look for continued sales growth across its commercial portfolio in the third quarter, particularly from Increlex and its pediatric endocrinology products. Growth in Desmoda and the recently relaunched Hemangeol (infantile hemangioma) could also support revenues.
Eton's recent launches and licensing deals could support revenue growth. Impavido, launched in the United States in late September 2026, is expected to have made a limited contribution to third-quarter sales. Investors will watch its initial market adoption and patient access. The exclusive U.S. licensing and supply agreement for Libervant (diazepam) buccal film adds another potential growth opportunity for Eton. However, with commercial availability planned for April 2027, subject to final FDA approval, the product is unlikely to contribute to third-quarter 2026 revenues. Investors will instead look for updates on regulatory progress and launch preparations.
Apart from revenue growth, profitability will be an important factor to watch in Eton's upcoming results. The company reported strong gross profit growth in the second quarter. The trend is also expected to continue in the upcoming quarter. However, higher research and development (R&D), and selling, general and administrative expenses could dampen the operating margin.
Eton has also raised its 2026 revenue guidance to more than $145 million in the second quarter, reflecting strong commercial performance. Investors will assess whether the company remains on track to achieve its revised revenue and whether another guidance increase is possible.
Finally, pipeline progress will remain in focus, particularly the planned Amglidia new drug application submission by the end of 2026, ASN-001 and ET-700 development, and the Increlex and Khindivi label expansion programs.
ETON's Earnings Surprise History
Eton has a mixed history of earnings surprises. The company missed earnings estimates in three of the trailing four quarters and beat in the remaining one, delivering a four-quarter average negative surprise of 11%. In the last reported quarter, ETON posted an earnings surprise of 218.18%.
ETON’s Stock Performance
Year to date, shares of Eton have skyrocketed 208.6% compared with the industry’s 11.3% growth.
Image Source: Zacks Investment Research
Earnings Whispers for ETON
Our proven model does not conclusively predict an earnings beat for ETON this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. That is not the case here, as you will see below. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter.
ETON’s Earnings ESP: Eton’s Earnings ESP is 0.00%.
ETON’s Zacks Rank: ETON has a Zacks Rank #3 at present.
Here are a few stocks worth considering from the healthcare space, as our model shows that these have the right combination of elements to beat on earnings this reporting cycle.
TGTX shares have surged 105.3% year to date. The company’s earnings missed estimates in three of the trailing four quarters and topped in the remaining one, delivering the average surprise of 184.65%.
Amneal Pharmaceuticals (AMRX - Free Report) has an Earnings ESP of +4.17% and a Zacks Rank #2 at present.
AMRX shares have gained 70.7% year to date. The company’s earnings beat estimates in the trailing four quarters, delivering the average surprise of 32.82%.
Iovance Biotherapeutics (IOVA - Free Report) has an Earnings ESP of +44.44% and a Zacks Rank #2 at present.
IOVA shares have skyrocketed 210.6% year to date. The company’s earnings beat estimates in the trailing four quarters, the average surprise being 16.82%. Iovance Biotherapeutics is scheduled to report third-quarter results on Nov. 5.
View the Zacks #1 Rank List
Image: Bigstock
ETON Gears Up to Report Q3 Earnings: What Can Investors Expect?
Key Takeaways
Eton Pharmaceuticals (ETON - Free Report) is scheduled to report third-quarter 2026 earnings on Nov. 5, 2026, after market close.
The Zacks Consensus Estimate for the to-be-reported quarter’s revenues is pegged at $42.2 million, while the same for the bottom line is pinned at earnings of 34 cents per share.
Let us see how things are likely to have shaped up for ETON in the to-be-reported quarter.
Factors Likely to Influence ETON's Q3 Results
Eton currently has 12 commercial products and five additional candidates in late-stage development. Growth in several of these products, particularly Increlex, Alkindi Sprinkle, Galzin and Carglumic Acid, helped drive the company’s first-half performance.
Investors will look for continued sales growth across its commercial portfolio in the third quarter, particularly from Increlex and its pediatric endocrinology products. Growth in Desmoda and the recently relaunched Hemangeol (infantile hemangioma) could also support revenues.
Eton's recent launches and licensing deals could support revenue growth. Impavido, launched in the United States in late September 2026, is expected to have made a limited contribution to third-quarter sales. Investors will watch its initial market adoption and patient access. The exclusive U.S. licensing and supply agreement for Libervant (diazepam) buccal film adds another potential growth opportunity for Eton. However, with commercial availability planned for April 2027, subject to final FDA approval, the product is unlikely to contribute to third-quarter 2026 revenues. Investors will instead look for updates on regulatory progress and launch preparations.
Apart from revenue growth, profitability will be an important factor to watch in Eton's upcoming results. The company reported strong gross profit growth in the second quarter. The trend is also expected to continue in the upcoming quarter. However, higher research and development (R&D), and selling, general and administrative expenses could dampen the operating margin.
Eton has also raised its 2026 revenue guidance to more than $145 million in the second quarter, reflecting strong commercial performance. Investors will assess whether the company remains on track to achieve its revised revenue and whether another guidance increase is possible.
Finally, pipeline progress will remain in focus, particularly the planned Amglidia new drug application submission by the end of 2026, ASN-001 and ET-700 development, and the Increlex and Khindivi label expansion programs.
ETON's Earnings Surprise History
Eton has a mixed history of earnings surprises. The company missed earnings estimates in three of the trailing four quarters and beat in the remaining one, delivering a four-quarter average negative surprise of 11%. In the last reported quarter, ETON posted an earnings surprise of 218.18%.
ETON’s Stock Performance
Year to date, shares of Eton have skyrocketed 208.6% compared with the industry’s 11.3% growth.
Image Source: Zacks Investment Research
Earnings Whispers for ETON
Our proven model does not conclusively predict an earnings beat for ETON this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. That is not the case here, as you will see below. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter.
ETON’s Earnings ESP: Eton’s Earnings ESP is 0.00%.
ETON’s Zacks Rank: ETON has a Zacks Rank #3 at present.
Eton Pharmaceuticals, Inc. Price and Consensus
Eton Pharmaceuticals, Inc. price-consensus-chart | Eton Pharmaceuticals, Inc. Quote
Stocks to Consider
Here are a few stocks worth considering from the healthcare space, as our model shows that these have the right combination of elements to beat on earnings this reporting cycle.
TG Therapeutics (TGTX - Free Report) has an Earnings ESP of +71.43% and flaunts a Zacks Rank #1 at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
TGTX shares have surged 105.3% year to date. The company’s earnings missed estimates in three of the trailing four quarters and topped in the remaining one, delivering the average surprise of 184.65%.
Amneal Pharmaceuticals (AMRX - Free Report) has an Earnings ESP of +4.17% and a Zacks Rank #2 at present.
AMRX shares have gained 70.7% year to date. The company’s earnings beat estimates in the trailing four quarters, delivering the average surprise of 32.82%.
Iovance Biotherapeutics (IOVA - Free Report) has an Earnings ESP of +44.44% and a Zacks Rank #2 at present.
IOVA shares have skyrocketed 210.6% year to date. The company’s earnings beat estimates in the trailing four quarters, the average surprise being 16.82%. Iovance Biotherapeutics is scheduled to report third-quarter results on Nov. 5.